Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review.
Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Burke J, Hua F, Apgar J, Talmor DS, Sauaia A, Liptzin DR, Veress LA, Yaffe MB. Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review. Res Pract Thromb Haemost. 2020 May; 4(4):524-531.